iRegene Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
62
- Latest Deal Type
-
Series C1
- Latest Deal Amount
-
$38.2M
- Investors
-
26
iRegene General Information
Description
Developer of chemically induced allogeneic cell therapies intended for the treatment of degenerative diseases. The company offers dopaminergic progenitor cell therapies and retinal degenerative disease treatments, thereby enabling pharmaceutical researchers to obtain human-specific cell types through a proprietary AI-driven chemical induction platform.
Contact Information
Website
cn.iregene.comCorporate Office
- Room 404, Building 2
- Number 618 Fenghuang Road, Shuangliu District
- Chengdu, Sichuan 610299
- China
Corporate Office
- Room 404, Building 2
- Number 618 Fenghuang Road, Shuangliu District
- Chengdu, Sichuan 610299
- China
iRegene Timeline
iRegene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC (Series C1) | 01-Jun-2026 | $38.2M | Completed | Generating Revenue | ||
| 12. Later Stage VC (Series C) | 05-Jan-2026 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B2) | 04-Sep-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series B1) | 11-Apr-2025 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B1) | Completed | Generating Revenue | ||||
| 8. Secondary Transaction - Private | 04-Nov-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 10-Oct-2024 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A1) | 28-Jan-2022 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 16-Nov-2021 | $18.8M | Completed | Generating Revenue | ||
| 4. Early Stage VC (Series A) | 06-Aug-2021 | $12.3M | $18.8M | Completed | Generating Revenue |
iRegene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
iRegene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
iRegene Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apricot Capital (Shanghai) | Venture Capital | Minority | ||
| Chengdu Venture Capital Group | Venture Capital | Minority | ||
| China Capital Management | PE/Buyout | Minority | ||
| GSR Ventures | Venture Capital | Minority | ||
| Guanghe Venture | Venture Capital | Minority |
iRegene FAQs
-
When was iRegene founded?
iRegene was founded in 2017.
-
Where is iRegene headquartered?
iRegene is headquartered in Chengdu, China.
-
What is the size of iRegene?
iRegene has 62 total employees.
-
What industry is iRegene in?
iRegene’s primary industry is Drug Discovery.
-
Is iRegene a private or public company?
iRegene is a Private company.
-
What is iRegene’s current revenue?
The current revenue for iRegene is .
-
How much funding has iRegene raised over time?
iRegene has raised $461M.
-
Who are iRegene’s investors?
Apricot Capital (Shanghai), Chengdu Venture Capital Group, China Capital Management, GSR Ventures, and Guanghe Venture are 5 of 26 investors who have invested in iRegene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
